All
Pre-Surgical Immunotherapy Identifies Potential Benefit, Risk of Recurrence in Melanoma
April 19th 2018For patients with melanoma, administration of a PD-1 checkpoint blockade therapy in the neoadjuvant setting – meaning it was given before the main treatment – could result in improved outcomes and better insight to patient responses.
FDA Grants Opdivo Priority Review for Small Cell Lung Cancer
April 19th 2018The Food and Drug Administration (FDA) granted priority review to a supplemental biologics license application for Opdivo (nivolumab) for the treatment of patients with small cell lung cancer with disease progression following two or more lines of therapy.
Frontline Opdivo-Yervoy Combo Shows Promise in Advanced Non-Small Cell Lung Cancer
April 17th 2018Most recently, the dynamic duo of Yervoy (ipilimumab) plus Opdivo (nivolumab) – both checkpoint inhibitors – extended average progression-free survival (PFS) rates more than three times than standard-of-care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) with high tumor mutational burden (TMB).